Next Article in Journal
Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies
Next Article in Special Issue
Acetonitrile Adducts of Tranexamic Acid as Sensitive Ions for Quantification at Residue Levels in Human Plasma by UHPLC-MS/MS
Previous Article in Journal
Original Contributions to the Chemical Composition, Microbicidal, Virulence-Arresting and Antibiotic-Enhancing Activity of Essential Oils from Four Coniferous Species
Previous Article in Special Issue
An Improved LC–MS/MS Method for the Analysis of Thirteen Cytostatics on Workplace Surfaces
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 14
Issue 11
10.3390/ph14111160
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

NanoUPLC-QTOF-MS/MS Determination of Major Rosuvastatin Degradation Products Generated by Gamma Radiation in Aqueous Solution

by
Lucija Dončević
1,
Ema Svetličić
2,
Amela Hozić
1,
Branka Mihaljević
3,
Dorota Jarmużek
4,
Ivana Tartaro Bujak
3,
Donata Pluskota-Karwatka
4,
Luka Ozdanovac
5,
Iva Džeba
3 and
Mario Cindrić
1,*
1
Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia
2
Department of Biochemical Bioengineering, Faculty of Food Technology and Biotechnology, University of Zagreb, Pierottijeva 6, 10000 Zagreb, Croatia
3
Division of Materials Chemistry, Ruđer Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia
4
Faculty of Chemistry, Adam Mickiewicz University in Poznan, Uniwersytetu Poznanskiego 8, 61-614 Poznan, Poland
5
Research and Development Ltd., PLIVA, Prilaz Baruna Filipovića 29, 10000 Zagreb, Croatia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(11), 1160; https://doi.org/10.3390/ph14111160
Submission received: 27 August 2021 / Revised: 4 November 2021 / Accepted: 10 November 2021 / Published: 13 November 2021
(This article belongs to the Special Issue Analytical Techniques in the Pharmaceutical Sciences)
Browse Figures
Versions Notes

Abstract

:
Rosuvastatin, a member of the statin family of drugs, is used to regulate high cholesterol levels in the human body. Moreover, rosuvastatin and other statins demonstrate a protective role against free radical-induced oxidative stress. Our research aimed to investigate the end-products of free radical-induced degradation of rosuvastatin. To induce the radical degradation, an aqueous solution of rosuvastatin was irradiated using different doses of gamma radiation (50–1000 Gy) under oxidative conditions. Rosuvastatin and related degradation products were separated on nanoC18 column under gradient elution, and identification was carried out on hyphenated nanoUPLC and nanoESI-QTOF mass spectrometer system. Elemental composition analysis using highly accurate mass measurements together with isotope fitting algorithm identified nine major degradation products. This is the first study of gamma radiation-induced degradation of rosuvastatin, where chemical structures, MS/MS fragmentation pathways and formation mechanisms of the resulting degradation products are detailly described. The presented results contribute to the understanding of the degradation pathway of rosuvastatin and possibly other statins under gamma radiation conditions.

1. Introduction

Rosuvastatin (RSV), chemically described as (E)-7-(4-(4-fluorophenyl)-6-isopropyl-2 -(N-methylmethylsulfonamide)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid, is a member of the class of statins [1]. Statins are effective cholesterol-lowering drugs, most commonly prescribed in the treatment of hyperlipidemia, mixed dyslipidemia, and related conditions [2]. In general, statins act as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is a rate-limiting enzyme in cholesterol synthesis, converting HMG-CoA to mevalonate [3]. Moreover, previous studies have demonstrated the antioxidant properties of RSV. It was hypothesized that RSV and other statins have a protective role against oxidative stress by reducing NAD(P)H oxidase and upregulating antioxidant enzyme superoxide dismutase [4,5]. In general, oxidative stress is defined as an imbalance between free radical reactions and a lack of defense against these reactions in living organisms. Among all free radicals, ●OH radical is one of the most reactive oxygen species (ROS) [6]. In addition to research of statin antioxidant potential in vivo [7,8,9], previous studies have also shown that statins could act against hydroxyl radicals generated in aqueous solutions [10]. Since large accumulation of reactive oxygen species and free radicals increases the risk for various cardiovascular and cerebrovascular diseases, the use of statins is also encouraged to prevent the occurrence of named diseases. One of the successful methods for the generation of free radicals in aqueous solutions is gamma radiolysis. The result of gamma irradiation of aqueous solution is water radiolysis described as [11,12]:
H2O ⇝ (0.28) ●OH + (0.06) H● + (0.27) e−aq + (0.05) H2 + (0.07) H2O2 + (0.27) H+
where the number in parentheses represents the radiolytic yield or G-value in µmol/J. Saturation of the solution with nitrous oxide quantitatively converts the aqueous electrons and hydrogen radicals to the ●OH radicals according to reactions presented in Equations (2) and (3) [12,13]. Thus, gamma radiolysis under oxidative conditions enables the study of only the ●OH radical reactions.
e−aq + N2O + H2O → N2 + −OH + ●OH
H● + N2O → ●OH + N2
The effect of gamma radiation-induced oxidation has previously been studied on various drugs to understand their antioxidant mode of action [14,15]. Furthermore, the degradation of pharmaceuticals caused by gamma radiation can also be used for remediation of drinking water and wastewater [16,17,18]. Since statins are widely consumed pharmaceuticals, they accumulate in wastewater and sewage worldwide and thus represent potential bioactive hazard for human health or animal and plant ecosystem [19,20,21,22]. It was reported earlier that rosuvastatin does not extensively metabolize in the human body and 77% of it excretes as unchanged. Correspondingly, rosuvastatin can reach concentrations of 552 ng/L in effluent and 604 ng/L in influent samples of sewage [19]. Consequently, from the ecological point of view, it is important to identify and characterize degradation products formed due to interactions with reactive radicals induced by gamma radiation of RSV aqueous solution.
A previous study has proposed reaction kinetics and degradation mechanisms of several statins following Cs-137 gamma irradiation [23]. To the best of our knowledge, no such studies have been conducted on RSV. However, a large number of analytical techniques were used for the identification and structural characterization of RSV under different stress conditions such as extreme pH and temperature, humidity, photoirradiation, and others [24,25,26]. Related impurities and metabolites of RSV were analyzed by RP-UPLC [24,27], LC-MS/MS [28], LC-MS/TOF [29] and with a combination of hyphenated analytical techniques like LC-MSn, LC-NMR, and H/D exchange [30] in order to deduce structural changes and degradation mechanisms of named molecules in aqueous solutions. A valuable insight into the structural characterization was gained through the use of micro- and nano-analytical chromatographic techniques in a sense of increased sensitivity and separation efficacy, and reduced sample consumption [31]. Although LC-MS is widely accepted method for the structural elucidation of unknown structures, even accurate mass measurement sometimes cannot discriminate molecules with a similar mass and composition [32]. Thus, for the unambiguous structural determination of unknown analytes, LC-MS can be coupled to methods such as Nuclear Magnetic Resonance (NMR) [33].
The main objectives of this work were to investigate the degradation of an aqueous solution of RSV affected by gamma radiation at different radiation doses, identify produced degradation molecules, and suggest mechanisms of their formation. Several degradative molecular mechanisms were interconnected with already familiar RSV or other statin degradation products formed in forced stability testing, metabolic degradation, or oxidative stress pathways [24,25,26,27,28,30,34]. While four of the nine detected degradation products were already known from the literature, in this study five previously unknown structures of RSV degradation products are described for the first time in detail with corresponding fragmentation pathways and formation mechanisms. Chromatographic and mass spectrometry nano-techniques were employed in this research to explicate the interaction of RSV with hydroxyl radicals under forced degradation conditions. Although nano-LC techniques were employed in the previous research for the purpose of RSV degradation product elucidation [34], the herein described use of high resolution (>20,000) mass spectrometer enabled the identification of large number of molecules in solely one MS and MS/MS analysis. Moreover, the highly accurate mass measurement with mass error of less than 2 ppm together with isotope-fitting algorithm provided the accurate prediction and calculation of unknown molecular structures without pairing to other analytical techniques.

2. Results and Discussion

2.1. Chromatographic Analysis of Irradiated Samples

Irradiated and non-irradiated RSV samples were analyzed under the same chromatographic and mass spectrometry conditions to estimate differences between non-irradiated RSV and RSV samples irradiated at doses of 50, 100, 200, 500, and 1000 Gy (Figure S1 in Supplementary Materials). A total of nine degradation products emerged after gamma irradiation of RSV molecule. Molecular structures of RSV forced degradation products are shown in Figure 1. Extracted ion chromatograms of irradiated samples at gamma radiation doses of 50 and 100 Gy implied production of seven degradation products A, C.1/C.2, D.1/D.2, E, and F. Further analysis of samples irradiated at 200, 500, and 1000 Gy showed the production of two additional degradation products B.1/B.2 (Figure 2). The radiation doses were selected according to the literature [16,17,18] concerning gamma remediation of wastewater where the dose of 1000 Gy was the most applied radiation dose for the remediation of pharmaceutical contaminated water. Although the obtained results of our research provide qualitative information about the structure of rosuvastatin degradation products, the design of the remediation process should aim to completely decompose the pollutant without creating harmful intermediates. Furthermore, complete removal of pollutants and/or harmful substances due to the diverse composition of water and toxicity is almost impossible to achieve using only one method. Therefore, a combination of methods such as ionizing radiation with for example H2O2, ozonation or TiO2 nanoparticles could improve the degradation efficacy [35,36].

2.2. Fragmentation Pathway of RSV

RSV with molecular formula C22H29N3O6FS and theoretical monoisotopic mass m/z 482.1761 was eluted at 18.71 min in the total ion chromatogram (TIC), as shown in Figure 2. The fragmentation of RSV was previously conducted using an Imaging MALDI-TOF mass spectrometer where three major product ions were formed (m/z 300, 272, and 258) and it was proposed that the protonation occurs in the nitrogen of the N-methylmethanesulfonamide of RSV molecule [37]. Detailed fragmentation study was performed using LC-QTOF-MS in ESI positive ion mode where the characteristic fragmentation ions of m/z 464, 446, 422, 404, 344, 300, 272, and 270 were observed [29,30]. The authors proposed similar fragmentation pathway as shown in our results and described below.
The fragmentation pathway of RSV (Figure 3) was induced by the elimination of the water molecule related to the C-3 and C-5 atoms (m/z 482.1760 → m/z 464.1653 → m/z 446.1553). The fragment ion at m/z 422.1549 was generated by the loss of −C2H4O2, whereas the fragment ion at m/z 404.1984 was formed by the loss of methyl sulfonyl group. Fragment ion at m/z 378.1282 was formed by the cleavage between C-5 and C-4 atoms. The same ion with additional loss of methyl sulfonyl group formed the fragment at m/z 300.1508. Ions at m/z 270.1409, 258.1402, and 217.1013 were produced by the loss of methyl sulfonyl group and −CH(OH)CH2CH(OH)CH2COOH at C-5 position with the extra cleavage of methyl group and isopropyl group of fragments at m/z 258.1402 and 217.1013, respectively. The ion at m/z 189.0827 was produced by the loss of methyl sulfonyl group, the cleavage between C-6 and C-7, and additional internal cleavages of the pyrimidine ring. The last significant fragment ion in the mass spectrum at m/z 133.0454 corresponds to the non-conjugated part of RSV molecule with molecular formula C5H9O4. A fragmentation pattern of RSV served as a starting point to deduce sub-structural information on degradation products A, B.1/B.2, C.1/C.2, D.1/D.2, E, and F after the comparison of RSV and RSV degradation products MS/MS spectra.

2.3. Characterization of Degradation Products

Analysis of TIC of irradiated and non-irradiated RSV samples revealed differences in the chromatograms and consequently in subtracted MS spectra. The nine precursor ions observed in the spectra of irradiated RSV samples were considered to originate from degradation products and used for subsequent accurate MS/MS analysis.
Previously, various methods were used to induce forced degradation of RSV where its impurities and degradation products were tentatively identified and analyzed. However, only a few studies looked into more detailed structural characteristics of the resulting products [29,30,34,38,39]. Rosuvastatin was found highly sensitive to UV degradation where two major products emerged with the same m/z as the drug. The products were characterized as polycyclic isomers of the drug because the formation of polycyclic benzoquinazoline isomers was previously reported. In the same study a degradation product having m/z of 498 was also formed by photodegradation, the authors suggested it to be rosuvastatin-N-oxide [1]. Although the product of m/z 498 was found in our research (products C.1/C.2), the MS/MS pattern did not match the named molecule. In the study by Shah et al. [30], a total of 11 RSV degradation products were formed under hydrolytic and photolytic conditions. The LC-MS analysis showed that five degradation products had the same m/z as RSV and six degradation products had the mass which was 18 Da lower than the drug. The proposed mechanism for acid hydrolysis is esterification of RSV to lactone which then undergoes hydrolysis and converts back to the drug together with its diastereoisomer. The main pathway of RSV under photolytic conditions was found to be cyclization reaction through 1,5-hydrogen shift [30]. Degradation products A, C.1/C.2, and E were earlier reported to be produced during photocatalysis of RSV with ZnO [29], although the structure of product E was described only at the level of molecular formula, and the C.1/C.2 isomers were not distinguished because the position of the hydroxyl substituent in the fluorophenyl ring was not determined. Degradation products B.1/B.2, D.1/D.2, and F along with the proposed formation mechanisms were not previously described in the literature. Experimental mass, calculated molecular formula, theoretical mass, RDB, and MS/MS fragment ions of RSV and degradation products are shown in Table 1.

2.3.1. Degradation Product A (m/z 480.1805)

Compound A was eluted and detected at relative retention time (RRt) 0.84 in the TIC (Figure 2). The compound [M + H]+ ion was observed at m/z 480.1806, which corresponds to the elemental composition of C22H30N3O7S. The proposed molecular formula of compound A differs from the RSV formula (C22H29N3O6FS) by the presence of additional atoms: oxygen and hydrogen, and the absence of a fluorine atom. As it is presented in Figure 4, the MS/MS analysis of degradation product A showed the same fragmentation pattern as RSV with the mass shift of 1.9957 Da on average, except for two fragments detected in the low mass region (m/z 199.0873 and 131.0496). Mass differences and fragmentation pattern indicated that the molecule of product A contains a hydroxyl group at the position of the fluorine substituent. The average mass shift of 1.9956 Da complements the mass difference of fluorine and hydroxyl radical, 18.9984 Da and 17.0027 Da, respectively. Therefore, it is proposed that compound A resulted by radical substitution of fluorine atom on RSV molecule (Scheme 1) and the chemical name is proposed as (E)-7-(4-(4-hydroxyphenyl)-6-isopropyl-2-(N-ethylmethylsulfonamide)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid.

2.3.2. Degradation Products B.1/B.2 (m/z 500.1867)

Compounds B.1 and B.2 were eluted and detected at RRt 0.78 and RRt 0.89, respectively, as it is shown on the TIC (Figure 2). Protonated ions [M + H]+ of both products were observed at m/z 500.1865, corresponding to the elemental composition of C22H31N3O7FS. Such identical molecular formulas indicate that B.1 and B.2 are a pair of isomers that differ from RSV in the presence of a water molecule. Therefore, it was proposed that the compounds resulted from the radical hydroxylation of the double bond between C-6 and C-7 (Scheme 2). In the previous study, it was reported that the addition of hydroxyl radical was favored to the position C-6 [29]. Our results are consistent with this finding. Compound B.2 resulted from the addition of hydroxyl radical to C-6 and is the major regioisomer formed (Figure 2). We expected such reactivity which is obvious because the addition to C-6 leads to a more stable intermediate formation (Scheme 2 (2.2)). The stabilization is provided by the resonance with the π electrons of the fluorophenyl and the pyrimidine rings (Scheme 2). When hydroxyl radical undergoes addition to C-7, only resonance with the π electrons of the fluorophenyl ring contributes to the intermediate product stabilization. However, hydroxyl radicals generated by water radiolysis often react non-selectively. Therefore, radical hydroxylation of the C-6=C-7 bond was not regioselective and B.1, which resulted from the addition to C-7, was also formed as a minor regioisomer (Figure 2). Extracted ion chromatogram of product B.2 displayed the double chromatographic peak at RRt 0.89 (Figure 2). Such observation indicated the co-elution of two compounds of the same molecular mass. Moreover, radical hydroxylation of RSV leads to the formation of an additional chiral center. It was assumed that the double peak emerged due to a mixture of two diastereoisomers of product B.2. Consequently, both peak areas at RRt 0.89 were taken into account for the measurement of B.1/B.2 ratio.
Furthermore, degradation products B.1 and B.2 were not formed when the smallest dosage of radiations were applied (50 and 100 Gy). This observation can be explained by the mechanistic comparison with degradation products: A, C.1, C.2, D.1, and D.2 that were formed by the substitution of hydroxyl radical with a hydrogen atom bonded to the highly conjugated benzene ring. In comparison to that, compounds B.1/B.2 were produced by the addition of hydroxyl radical to the C-6=C-7 bond, which concludes that the radical substitution reaction occurs more readily than the radical addition reaction.
The formation of B.1 in difference to B.2 was confirmed by diagnostic fragments m/z 175.0736 and 147.0663 as seen in the MS/MS spectrum of the hydroxylation product B.1 (Figure 5). Besides two named diagnostic fragments, the remaining ions were the same in observed MS/MS spectra of both B.1 and B.2 product. Detection of both products could be attributed to the maximum sensitivity and resolution due to the utilization of nanoUPLC. The hydroxylation of RSV was additionally supported by the neutral loss of water molecule (18.0098 Da) from the precursor ion, m/z 500.1865 → m/z 482.1767 as is presented in Figure 5. The names of compounds B.1 and B.2 are proposed as 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamide)pyrimidin-5-yl)-3,5,6-trihydroxyheptanoic acid, and 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfo namide)pyrimidin-5-yl)-3,5,7-trihydroxyheptanoic acid, respectively.

2.3.3. Degradation Products C.1/C.2 (m/z 498.1710)

Compounds C.1 and C.2 were eluted and detected at RRt 0.88 and RRt 0.94, respectively, as it is shown in TIC (Figure 2). Accompanied MS spectra showed the presence of [M + H]+ ion signals at m/z 498.1709. The products C.1/C.2 were previously described in the literature, but mechanisms of their formation were not proposed and the position of the hydroxyl substituents in the fluorophenyl ring was not determined [29]. Elemental composition analyses of isomers C.1/C.2 were matched to the molecular formula C22H29N3O7FS. The identical MS/MS spectra of both products showed an average mass increment of 15.9943 Da in comparison to the fragmentation pattern of RSV (Figure 6). The mass increment can be explained by the addition of hydroxyl group to the fluorophenyl ring of RSV molecule. The fragment ions observed at m/z 133.0452, 189.0829, and 258.1404 were identical to the ions observed in mass spectra obtained from non-irradiated RSV sample. The named three fragments did not comprise structural information about addition of hydroxyl group to the fluorophenyl of RSV molecule. The mechanism assumes that C.1 and C.2 were formed by substitution of the hydrogen atom present in the fluorophenyl ring in the ortho- (Scheme 3 (2.1)) and meta- (Scheme 3 (2.2)) position by the hydroxyl radical. Spectra obtained after MS/MS analysis of products C.1 and C.2 did not indicate diagnostic ions and therefore did not distinguish the position of attached hydroxyl group to the fluorophenyl group of the RSV molecule. However, fragmentation pathway and ion transition m/z 286.1352 → m/z 258.1404 clearly pointed out hydroxyl group incorporation in the the fluorophenyl ring. In the literature, similar reactivity of hydroxyl radical towards chlorobenzene was previously reported [40]. Also, the ratio of the regioisomers formed in the reaction with chlorobenzene was similar to the ratio of C.1/C.2 which was found to be equal to 3/1 (Figure 2). The formation of C.1 as a proposed major isomer indicates that the inductive effect of fluorine is more efficient in the stabilization of intermediate radical formed in the substitution reaction than the resonance effect provided by the RSV pyrimidine ring. Resulted products C.1 and C.2 can be named as (E)-7-(4-(4-fluoro-3-hydroxyphenyl)-6-isopropyl- 2-(N-methylmethylsulfonamide) pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid for C.1 and (E)-7-(4-(4-fluoro-2- hydroxyphenyl)-6-isopropyl-2-(N-methylmethylsulfonamide) pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid for compound C.2.

2.3.4. Degradation Products D.1/D.2 (m/z 514.1659)

Compounds D.1 and D.2 were eluted and detected at RRt 0.78 and RRt 0.84, respectively, as it is shown in TIC (Figure 2). In the MS spectra, signals derived from [M + H]+ ions were observed at m/z 514.1655. This corresponds to elemental composition C22H29N3O8FS, the same for both products. Precursor ions of D.1/D.2 relative to products C.1/C.2 and RSV were characterized by a mass increment of 15.9946 Da and 31.9895 Da, respectively. Besides, fragment ions signals observed at m/z 496.1547, 478.1418, 436.1346, and 302.1279 showed the same mass shift of 15.9949, on average, compared to the MS/MS fragment ions signals of C.1/C.2 (Figure 7). The shifted fragment ions signals showed the same mass increment relative to the estimated relationship between C.1/C.2 and RSV, which indicates the presence of two hydroxyl groups in the fluorophenyl moieties in the structures of D.1/D.2. Therefore D.1/D.2 can be considered as derivatives of C.1/C.2, resulting from the substitution of a hydrogen atom in the fluorohydroxyphenyl ring with a second hydroxyl radical. As can be observed in Figure 2, one of the double-substituted products was formed in significantly higher quantity relative to the other. After D.1/D.2 MS/MS and spectral differential display analysis, it was not possible to establish exact position of the second hydroxyl group in the fluorohydroxyphenyl ring or to pinpoint diagnostic peaks for specific compound. It can only be supposed, based on the ratio of C.1/C.2 formation, that position next to the fluoro substituent is more favorable for a hydroxyl radical attack than other positions in the benzene ring. The mechanism responsible for the formation of D.1/D.2 from C.1/C.2 is most likely analogous to that proposed for giving rise C.1/C.2 from RSV. Chemical name of product D.1 was proposed as (E)-7-(4-(4-fluoro-3,X-dihydroxyphenyl)-6-isopropyl-2-(N-methylmethylsulfon amide)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid, and of product D.2 as (E)-7-(4-(4-fluoro-2,X-dihydroxyphenyl)-6-isopropyl-2-(N-methylmethylsulfonamide)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid.

2.3.5. Degradation Product E (m/z 480.1605)

It was determined from TIC that product E eluted at RRt 1.09 (Figure 2). The compound [M + H]+ ion signal was observed at m/z 480.1600, which corresponded to molecular formula C22H27N3O6FS. Fragment ions signals observed in the product MS/MS spectra at m/z 189.0830, 300.1505, and 378.1284 (Figure 8) were also seen in the fragmentation pathway of RSV (Figure 3). The formation of a compound with the same molecular formula as found for E was previously reported, but the structure of the compound and the mechanism for its formation were not proposed [29]. Nevertheless, it was found that the product structure had a higher ring and double bond equivalent (RDB) value compared to this one of RSV (10.5 vs 9.5). Herein we propose that the product E is formed in the radical intramolecular cyclization (Scheme 4). The process is initiated by an attack of a hydroxyl radical which abstracts hydrogen atom attached to α carbon atom of the RSV heptanoic acid side chain (Scheme 4 (1)). This leads to the formation of a resonance stabilized intermediate (Scheme 4 (2)). In the next step, the abstraction of the hydrogen atom of the chain δ hydroxyl group (Scheme 4 (3)) initiates an intramolecular cyclization leading to the formation of the substituted tetrahydrofuran ring (Scheme 4 (4)). The presence of the additional ring can explain the higher RDB value found for E in comparison to RSV. Support for the structure proposed for E was also provided by the fragment ions signals observed in the compound MS/MS spectra at m/z 462.1492 (loss of hydroxyl group), 436.1700 (loss of carboxylic group), 392.1440, 378.1284, 300.1505, 270.1403 (tetrahydrofuran ring cleavages) and m/z 256.1244, 201.0826, and 149.0713 (dissociation of the entire substituted tetrahydrofuran ring). Corresponding molecular formula and structure of product E was proposed as (E)-5-(2-(4-(4- fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamide)pyrimidin-5-yl)vinyl)-3-hydroxytetrahydrofuran-2-carboxylic acid.

2.3.6. Degradation Product F (m/z 436.1706)

Compound F was eluted and detected at RRt 1.21 in TIC (Figure 2). The compound [M + H]+ ion signal observed at m/z 436.1711 was matched to the molecular formula C21H27N3O4FS. Based on results derived from the compound MS/MS spectra (Figure 9) and elemental composition analysis, it was concluded that product F was most likely formed by decarboxylation of compound E (Scheme 5). It is worth noticing that collision energy needed for the induction of the compound fragmentation was equal to 45 V, which is approximately two times higher than collision energy used for product E fragmentation. The cyclization of statins was previously described in a paper dealing with the influence of gamma irradiation on fluvastatin. In that work, it was suggested that the tetrahydrofuran derivative of fluvastatin is formed by the loss of CO2 followed by cyclization [23]. Contrary to this, we propose the reverse order of the processes. We suggest that first, as a result of cyclization, product E is formed, the decarboxylation of which leads to the formation of compound F. The name of product F was proposed as (E)-N-(4-(4-fluorophenyl)-5-(2-(4-hydroxytetrahydrofuran-2-yl)vinyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide.

3. Materials and Methods

3.1. Raw Materials

Analytical grade rosuvastatin calcium (>99%), sodium dihydrogen phosphate (≥99.9%), formic acid (>98%), leucine enkephalin (>98%), and isopropanol (>99%) were obtained from Sigma-Aldrich (St. Louis, MO, USA). High purity nitrous oxide was purchased from Messer Croatia Plin (Zaprešić, Croatia) and acetonitrile (≥99.9%) from Merck Millipore (Burlington, MA, USA). Ultrapure water (18 MΩ·cm) was generated in-house using a Milli-Q System from Merck Millipore (Burlington, MA, USA).

3.2. Sample Preparation and Irradiation

A stock solution of RSV in the concentration of 0.1 mg/mL was prepared in the sodium dihydrogen phosphate buffer solution (pH 6.5; 0.01 M). A volume of 3 mL of stock solution was then saturated with nitrous oxide for 15 min at a flow rate of 1 mL/min. The solution prepared was irradiated using panoramic 60Co source situated in the Radiation Chemistry and Dosimetry Laboratory at the Ruđer Bošković Institute. RSV sample solutions were subjected to gamma radiation at five radiation doses (50, 100, 200, 500, and 1000 Gy) and the dose rate of 5.8 Gy/s. The temperature of the radiation chamber was 18 °C. The radiation dose rate was determined using an ethanol-chlorobenzene (90:10, v/v) dosimetry system, according to the standard ISO 51538:2017.

3.3. NanoUPLC-NanoESI-QTOF Analysis

Non-irradiated solution of RSV and irradiated samples were separated on a Waters (Milford, MA, USA) nanoAcquity UPLC system equipped with nanoAcquity UPLC 2G-V/M Symetry C18 Trap Column (100 Å, 5 μm, 180 μm × 20 mm) and nanoAcquity UPLC BEH130 C18 Analytical Column (130 Å, 1.7 μm, 100 μm × 100 mm). The injection volume was 3 μL and the column temperature was 40 °C. Mobile phase consisted out of solvent A (0.1% (v/v) formic acid) and solvent B (0.005% (v/v) formic acid in acetonitrile). Isocratic delivery of solvent A to the trap column was performed at a flow rate of 15 μL/min for 2 min. Samples were eluted under gradient elution conditions with a flow rate of 1 μL/min and run time of 32 min. The following elution gradient was used: 0–3 min, 80% solvent A; 3–24 min, 45% solvent A; 24–27 min, 1% solvent A; 27–29 min, 80% solvent A; 29–32 min, 80% solvent A. UPLC system was coupled to the nanoESI-QTOF Synapt G2-Si mass spectrometer (Waters, Milford, MA, USA). The instrument parameters were set using the MassLynx software v4.1. (Waters, Milford, MA, USA).
The MS and MS/MS data were collected in high-resolution acquisition mode, covering a mass range between 50 and 1000 Da. Parameters were set as follows: positive ion mode, nitrogen flow of 1.0 bar with a source temperature of 150 °C, the capillary voltage 4.2 kV, and the cone voltage 40 V. The spectral acquisition time was 1 s for MS and 0.5 s for MS/MS analysis. The mass accuracy of the raw data was corrected by infusing 1 ng/μL leucine enkephalin dissolved in isopropanol and 0.1% (v/v) formic acid (50:50, v/v; 556.2771 Da [M + H]+ and 120.0813 Da [M + H]+). Leucine enkephalin was infused into the mass spectrometer at the flow rate of 0.4 µL/min every 1 min to ensure high mass accuracy. The collision energy of 25 V was applied for all precursor ions, except for product F where collision energy of 45 V was applied.
Elemental composition analysis was performed in duplicates to fit and calculate unambiguous molecular formulas. The raw data were processed with MassLynx v4.1 (software equipped with isotope fitting algorithm MassFragment). Accurate mass measurement (<2 ppm), isotope pattern-based implementation (i-FIT algorithm), ring and double bond equivalent (RDB) 1.5–50, and 0–500 C, 0–1000 H, 0–6 S, 0–2 F, 0–200 O, 0–200 N, 0–8 Cl and 0–8 Br were used in elemental composition analysis for identification and confirmation of precursor and product ion fragments.

4. Conclusions

In this study, degradation products of gamma-induced irradiation of RSV are described for the first time. Overall nine degradation products are described of which four were correlated to the same or similar products generated by ZnO photocatalysis of RSV [29]. Remaining five products have never been described in the literature before this study. The essential part of unknown structure identification of degradation products was performed using a rapid and sensitive method based on nanoUPLC and nanoESI-QTOF. The named method enabled accurate mass analysis of products and precursor ions (<2 ppm) which was necessary for unambiguous structural identification and understanding of associated radical formation mechanisms. It was deduced that in addition to cyclization and decarboxylation caused by ●OH radical interactions (products E and F), ●OH radicals are attracted primarily to the conjugated part of a molecule with an excess of electrons (products A, B.1/B.2, C.1/C.2, and D.1/D.2). The revealed interactions between rosuvastatin and degradation product molecules, and ●OH radicals provide valuable information for future research concerning synthesis of new statin molecules, as well as understanding the mechanism of antioxidant action of RSV which has so far been only a hypothesis. Furthermore, since gamma radiation is considered as a possible method for wastewater remediation, our study confirms the degradation of rosuvastatin by applying small doses of radiation.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ph14111160/s1, Figure S1: Total Ion Current (TIC) chromatograms of irradiated (A) and non-irradiated RSV samples (B).

Author Contributions

Conceptualization, I.D., B.M. and I.T.B.; methodology, L.D., E.S. and D.J.; validation, L.D., E.S. and M.C.; formal analysis, L.D., A.H. and I.T.B.; investigation, L.D. and A.H.; resources, B.M. and M.C.; data curation, L.D. and A.H.; writing—original draft preparation, L.D., E.S., L.O. and M.C.; writing—review and editing, A.H., D.J., I.T.B., D.P.-K., B.M. and M.C.; visualization, L.D., E.S. and L.O.; supervision, B.M. and M.C.; project administration, M.C.; funding acquisition, M.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the European Regional Development Fund, grant number KK.01.1.1.07.0023.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are openly available in Mendeley Data at doi: 10.17632/cg3hmww4t3.1, reference number [41].

Acknowledgments

The contribution of the funds is gratefully acknowledged. We would like to express a special appreciation to Saša Kazazić for useful discussions and his assistance with preliminary results.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Khedr, A.; Belal, F.; Ibrahim, F.; Elawady, T. Analysis of rosuvastatin stress degradation behavior using liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry. Anal. Methods 2013, 5, 6494–6502. [Google Scholar] [CrossRef]
  2. Carswell, C.I.; Plosker, G.L.; Jarvis, B. Rosuvastatin. Drugs 2002, 62, 2075–2085. [Google Scholar] [CrossRef] [PubMed]
  3. Maron, D.J.; Fazio, S.; Linton, M.F. Current Perspectives on Statins. Circulation 2000, 101, 207–213. [Google Scholar] [CrossRef] [Green Version]
  4. Schupp, N.; Schmid, U.; Heidland, A.; Stopper, H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008, 199, 278–287. [Google Scholar] [CrossRef] [PubMed]
  5. Mahalwar, R.; Khanna, D. Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders. Eur. J. Pharmacol. 2013, 711, 57–62. [Google Scholar] [CrossRef]
  6. Zang, L.; He, H.; Xu, Q.; Yu, Y.; Zheng, N.; Liu, W.; Hayashi, T.; Tashiro, S.I.; Onodera, S.; Ikejima, T. Reactive oxygen species H2O2 and OH, but not O2− promote oridonin-induced phagocytosis of apoptotic cells by human histocytic lymphoma U937 cells. Int. Immunopharmacol. 2013, 15, 414–423. [Google Scholar] [CrossRef]
  7. Koksal, M.; Eren, M.A.; Turan, M.N.; Sabuncu, T. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. Eur. J. Intern. Med. 2011, 22, 249–253. [Google Scholar] [CrossRef]
  8. Otto, A.; Fontaine, J.; Tschirhart, E.; Fontaine, D.; Berkenboom, G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: Implication of the NAD(P)H oxidase pathway. Br. J. Pharmacol. 2006, 148, 544–552. [Google Scholar] [CrossRef]
  9. Deng, J.; Wu, G.; Yang, C.; Li, Y.; Jing, Q.; Han, Y. Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats. J. Transl. Med. 2015, 13, 1–9. [Google Scholar] [CrossRef] [Green Version]
  10. Umeda, R.; Takanari, H.; Ogata, K.; Matsumoto, S.; Kitano, T.; Ono, K.; Tokumaru, O. Direct free radical scavenging effects of water-soluble HMG-CoA reductase inhibitors. J. Clin. Biochem. Nutr. 2019, 64, 20–26. [Google Scholar] [CrossRef] [Green Version]
  11. Le Caër, S. Water Radiolysis: Influence of Oxide Surfaces on H2 Production under Ionizing Radiation. Water 2011, 3, 235–253. [Google Scholar] [CrossRef] [Green Version]
  12. Song, W.; Xu, T.; Cooper, W.J.; Dionysiou, D.D.; De La Cruz, A.A.; O’Shea, K.E. Radiolysis studies on the destruction of microcystin-LR in aqueous solution by hydroxyl radicals. Environ. Sci. Technol. 2009, 43, 1487–1492. [Google Scholar] [CrossRef] [Green Version]
  13. Yakabuskie, P.A.; Joseph, J.M.; Stuart, C.R.; Wren, J.C. Long-term γ-radiolysis kinetics of NO3− and NO2− solutions. J. Phys. Chem. A 2011, 115, 4270–4278. [Google Scholar] [CrossRef] [PubMed]
  14. Khouri, H.; Collin, F.; Bonnefont-Rousselot, D.; Legrand, A.; Jore, D.; Gardes-Albert, M. Radical-induced oxidation of metformin. Eur. J. Biochem. 2004, 271, 4745–4752. [Google Scholar] [CrossRef] [PubMed]
  15. Collin, F.; Khoury, H.; Bonnefont-Rousselot, D.; Thérond, P.; Legrand, A.; Jore, D.; Gardès-Albert, M. Liquid chromatographic/electrospray ionization mass spectrometric identification of the oxidation end-products of metformin in aqueous solutions. J. Mass Spectrom. 2004, 39, 890–902. [Google Scholar] [CrossRef] [PubMed]
  16. Rivera-Utrilla, J.; Sánchez-Polo, M.; Ferro-García, M.Á.; Prados-Joya, G.; Ocampo-Pérez, R. Pharmaceuticals as emerging contaminants and their removal from water. A review. Chemosphere 2013, 93, 1268–1287. [Google Scholar] [CrossRef]
  17. Abdel Rahman, R.O.; Hung, Y.-T. Application of Ionizing Radiation in Wastewater Treatment: An Overview. Water 2019, 12, 19. [Google Scholar] [CrossRef] [Green Version]
  18. Wang, J.; Chu, L. Irradiation treatment of pharmaceutical and personal care products (PPCPs) in water and wastewater: An overview. Radiat. Phys. Chem. 2016, 125, 56–64. [Google Scholar] [CrossRef]
  19. Lee, H.B.; Peart, T.E.; Lewina Svoboda, M.; Backus, S. Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples. Chemosphere 2009, 77, 1285–1291. [Google Scholar] [CrossRef]
  20. Ashfaq, M.; Nawaz Khan, K.; Saif Ur Rehman, M.; Mustafa, G.; Faizan Nazar, M.; Sun, Q.; Iqbal, J.; Mulla, S.I.; Yu, C.P. Ecological risk assessment of pharmaceuticals in the receiving environment of pharmaceutical wastewater in Pakistan. Ecotoxicol. Environ. Saf. 2017, 136, 31–39. [Google Scholar] [CrossRef]
  21. Golovko, O.; Kumar, V.; Fedorova, G.; Randak, T.; Grabic, R. Seasonal changes in antibiotics, antidepressants/psychiatric drugs, antihistamines and lipid regulators in a wastewater treatment plant. Chemosphere 2014, 111, 418–426. [Google Scholar] [CrossRef] [PubMed]
  22. Martín, J.; Buchberger, W.; Alonso, E.; Himmelsbach, M.; Aparicio, I. Comparison of different extraction methods for the determination of statin drugs in wastewater and river water by HPLC/Q-TOF-MS. Talanta 2011, 85, 607–615. [Google Scholar] [CrossRef] [PubMed]
  23. Razavi, B.; Song, W.; Santoke, H.; Cooper, W.J. Treatment of statin compounds by advanced oxidation processes: Kinetic considerations and destruction mechanisms. Radiat. Phys. Chem. 2011, 80, 453–461. [Google Scholar] [CrossRef]
  24. Zakrajšek, J.; Bevc-Černilec, K.; Bohanec, S.; Urleb, U. Optimization of UPLC method for simultaneous determination of rosuvastatin and rosuvastatin degradation products. Acta Chim. Slov. 2017, 64, 968–979. [Google Scholar] [CrossRef] [Green Version]
  25. Mostafa, N.M.; Badawey, A.M.; Lamie, N.T.; Abd El-Aleem, A.E.A.B. Selective chromatographic methods for the determination of Rosuvastatin calcium in the presence of its acid degradation products. J. Liq. Chromatogr. Relat. Technol. 2014, 37, 2182–2196. [Google Scholar] [CrossRef]
  26. Mehta, T.N.; Patel, A.K.; Kulkarini, G.M.; Suubbaiah, G. Determination of rosuvastatin in the presence of its degradation products by a stability-indicating LC method. J. AOAC Int. 2005, 88, 1142–1147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Trivedi, R.K.; Patel, M.C. Development and validation of a stability indicating RP-UPLC method for determination of quetiapine in pharmaceutical dosage form. Sci. Pharm. 2011, 79, 97–111. [Google Scholar] [CrossRef] [Green Version]
  28. Zhang, D.; Zhang, J.; Liu, X.; Wei, C.; Zhang, R.; Song, H.; Yao, H.; Yuan, G.; Wang, B.; Guo, R. Validated LC-MS/MS Method for the Determination of Rosuvastatin in Human Plasma: Application to a Bioequivalence Study in Chinese Volunteers. Pharmacol. Pharm. 2011, 02, 341–346. [Google Scholar] [CrossRef] [Green Version]
  29. Segalin, J.; Sirtori, C.; Jank, L.; Lima, M.F.S.; Livotto, P.R.; Machado, T.C.; Lansarin, M.A.; Pizzolato, T.M. Identification of transformation products of rosuvastatin in water during ZnO photocatalytic degradation through the use of associated LC-QTOF-MS to computational chemistry. J. Hazard. Mater. 2015, 299, 78–85. [Google Scholar] [CrossRef]
  30. Shah, R.P.; Sahu, A.; Singh, S. LC-MS/TOF, LC-MSn, on-line H/D exchange and LC-NMR studies on rosuvastatin degradation and in silico determination of toxicity of its degradation products: A comprehensive approach during drug development. Anal. Bioanal. Chem. 2013, 405, 3215–3231. [Google Scholar] [CrossRef]
  31. Gama, M.R.; Collins, C.H.; Bottoli, C.B.G. Nano-Liquid Chromatography in Pharmaceutical and Biomedical Research. J. Chromatogr. Sci. 2013, 51, 694–703. [Google Scholar] [CrossRef] [PubMed]
  32. De Vijlder, T.; Valkenborg, D.; Lemière, F.; Romijn, E.P.; Laukens, K.; Cuyckens, F. A tutorial in small molecule identification via electrospray ionization-mass spectrometry: The practical art of structural elucidation. Mass Spectrom. Rev. 2018, 37, 607–629. [Google Scholar] [CrossRef] [PubMed]
  33. Gathungu, R.M.; Kautz, R.; Kristal, B.S.; Bird, S.S.; Vouros, P. The integration of LC-MS and NMR for the analysis of low molecular weight trace analytes in complex matrices. Mass Spectrom. Rev. 2020, 39, 35–54. [Google Scholar] [CrossRef] [PubMed]
  34. Machado, T.C.; Pizzolato, T.M.; Arenzon, A.; Segalin, J.; Lansarin, M.A. Photocatalytic degradation of rosuvastatin: Analytical studies and toxicity evaluations. Sci. Total Environ. 2015, 502, 571–577. [Google Scholar] [CrossRef]
  35. Jinga, L.I.; Popescu-Pelin, G.; Socol, G.; Mocanu, S.; Tudose, M.; Culita, D.C.; Kuncser, A.; Ionita, P. Chemical Degradation of Methylene Blue Dye Using TiO2/Au Nanoparticles. Nanomaterials 2021, 11, 1605. [Google Scholar] [CrossRef] [PubMed]
  36. Saquib, M.; Abu Tariq, M.; Haque, M.M.; Muneer, M. Photocatalytic degradation of disperse blue 1 using UV/TiO2/H2O2 process. J. Environ. Manag. 2008, 88, 300–306. [Google Scholar] [CrossRef] [PubMed]
  37. Cristoni, S.; Brioschi, M.; Rizzi, A.; Sironi, L.; Gelosa, P.; Tremoli, E.; Bernardi, L.R.; Banfi, C. Analysis of rosuvatatin by imaging mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 3483–3487. [Google Scholar] [CrossRef] [PubMed]
  38. Kishore, C.R.P.; Mohan, G.V.K. Structural identification and estimation of Rosuvastatin calcium related impurities in Rosuvastatin calcium tablet dosage form. Anal. Chem. Res. 2017, 12, 17–27. [Google Scholar] [CrossRef]
  39. Reddy, G.V.R.; Reddy, B.V.; Haque, S.W.; Gautam, H.D.; Kumar, P.; Kumar, A.P.; Park, J.H. Development and validation of a stability-indicating uplc method for rosuvastatin and its related impurities in pharmaceutical dosage forms. Quim. Nova 2011, 34, 250–255. [Google Scholar] [CrossRef] [Green Version]
  40. Choure, S.C.; Bamatraf, M.M.M.; Rao, B.S.M.; Das, R.; Mohan, H.; Mittal, J.P. Hydroxylation of chlorotoluenes and cresols: A pulse radiolysis, laser flash photolysis, and product analysis study. J. Phys. Chem. A 1997, 101, 9837–9845. [Google Scholar] [CrossRef]
  41. Dončević, L.; Svetličić, E.; Hozić, A.; Cindrić, M. Dataset for: Determination of Rosuvastatin Degradation Products. 2020. Available online: https://data.mendeley.com/datasets/cg3hmww4t3/1 (accessed on 9 November 2021).
Pharmaceuticals 14 01160 g001 550
Figure 1. Structures and belonging molecular weights in Da of rosuvastatin (RSV) molecule and degradation products induced by radiation dose up to 1000 Gy: A, B.1/B.2, C.1/C.2, D.1/D.2, E, and F.
Figure 1. Structures and belonging molecular weights in Da of rosuvastatin (RSV) molecule and degradation products induced by radiation dose up to 1000 Gy: A, B.1/B.2, C.1/C.2, D.1/D.2, E, and F.
Pharmaceuticals 14 01160 g001
Pharmaceuticals 14 01160 g002 550
Figure 2. Extracted ion chromatograms of RSV (Rt 18.71) and gamma radiation-induced degradation products at 1000 Gy with observed relative retention time (RRt). Intensities of degradation products are normalized to the RSV principal peak. Peak areas of degradation peaks are expressed as percent area of the RSV principal peak. Fraction of extracted peak masses of B.1/B.2, C.1/C.2, and D.1/D.2 is calculated by dividing isobaric peak areas.
Figure 2. Extracted ion chromatograms of RSV (Rt 18.71) and gamma radiation-induced degradation products at 1000 Gy with observed relative retention time (RRt). Intensities of degradation products are normalized to the RSV principal peak. Peak areas of degradation peaks are expressed as percent area of the RSV principal peak. Fraction of extracted peak masses of B.1/B.2, C.1/C.2, and D.1/D.2 is calculated by dividing isobaric peak areas.
Pharmaceuticals 14 01160 g002
Pharmaceuticals 14 01160 g003 550
Figure 3. Fragmentation MS/MS spectra of RSV [M + H]+ ion (precursor ion mass m/z 482.1760) obtained by using collision energy of 25 V.
Figure 3. Fragmentation MS/MS spectra of RSV [M + H]+ ion (precursor ion mass m/z 482.1760) obtained by using collision energy of 25 V.
Pharmaceuticals 14 01160 g003
Pharmaceuticals 14 01160 g004 550
Figure 4. Fragmentation MS/MS spectra of product A [M + H]+ ion (precursor ion mass m/z 480.1806) obtained by using collision energy of 25 V.
Figure 4. Fragmentation MS/MS spectra of product A [M + H]+ ion (precursor ion mass m/z 480.1806) obtained by using collision energy of 25 V.
Pharmaceuticals 14 01160 g004
Pharmaceuticals 14 01160 sch001 550
Scheme 1. Proposed mechanism of the compound A formation by radical substitution on RSV.
Scheme 1. Proposed mechanism of the compound A formation by radical substitution on RSV.
Pharmaceuticals 14 01160 sch001
Pharmaceuticals 14 01160 g005 550
Figure 5. Fragmentation MS/MS spectra of product B.1 [M + H]+ ion (precursor ion mass m/z 500.1865) obtained by using collision energy of 25 V.
Figure 5. Fragmentation MS/MS spectra of product B.1 [M + H]+ ion (precursor ion mass m/z 500.1865) obtained by using collision energy of 25 V.
Pharmaceuticals 14 01160 g005
Pharmaceuticals 14 01160 sch002 550
Scheme 2. Proposed mechanism of the compounds B.1 and B.2 formation by radical hydroxylation of RSV. Resonance structures showing stabilization of the intermediate product leading to the compound B.2 generation.
Scheme 2. Proposed mechanism of the compounds B.1 and B.2 formation by radical hydroxylation of RSV. Resonance structures showing stabilization of the intermediate product leading to the compound B.2 generation.
Pharmaceuticals 14 01160 sch002
Pharmaceuticals 14 01160 g006 550
Figure 6. Fragmentation MS/MS spectra of product C.1 [M + H]+ ion (precursor ion mass m/z 498.1709) obtained by using collision energy of 25 V.
Figure 6. Fragmentation MS/MS spectra of product C.1 [M + H]+ ion (precursor ion mass m/z 498.1709) obtained by using collision energy of 25 V.
Pharmaceuticals 14 01160 g006
Pharmaceuticals 14 01160 sch003 550
Scheme 3. Proposed mechanism of the compounds C.1/C.2 formation by radical substitution on RSV.
Scheme 3. Proposed mechanism of the compounds C.1/C.2 formation by radical substitution on RSV.
Pharmaceuticals 14 01160 sch003
Pharmaceuticals 14 01160 g007 550
Figure 7. Fragmentation MS/MS spectra of product D.1 [M + H]+ ion (precursor ion m/z 514.1655) obtained by using collision energy of 25 V.
Figure 7. Fragmentation MS/MS spectra of product D.1 [M + H]+ ion (precursor ion m/z 514.1655) obtained by using collision energy of 25 V.
Pharmaceuticals 14 01160 g007
Pharmaceuticals 14 01160 g008 550
Figure 8. Fragmentation MS/MS spectra of product E [M + H]+ ion (precursor ion mass m/z 480.1600) obtained by using collision energy of 25 V.
Figure 8. Fragmentation MS/MS spectra of product E [M + H]+ ion (precursor ion mass m/z 480.1600) obtained by using collision energy of 25 V.
Pharmaceuticals 14 01160 g008
Pharmaceuticals 14 01160 sch004 550
Scheme 4. Mechanism of the product E formation by radical-induced cyclization of RSV.
Scheme 4. Mechanism of the product E formation by radical-induced cyclization of RSV.
Pharmaceuticals 14 01160 sch004
Pharmaceuticals 14 01160 g009 550
Figure 9. Fragmentation MS/MS spectra of product F [M + H]+ ion (product ion mass m/z 436.1711) obtained by using collision energy of 45 V.
Figure 9. Fragmentation MS/MS spectra of product F [M + H]+ ion (product ion mass m/z 436.1711) obtained by using collision energy of 45 V.
Pharmaceuticals 14 01160 g009
Pharmaceuticals 14 01160 sch005 550
Scheme 5. Mechanism of the product F formation by decarboxylation of product E.
Scheme 5. Mechanism of the product F formation by decarboxylation of product E.
Pharmaceuticals 14 01160 sch005
Table
Table 1. nanoLC-nanoESI-QTOF/MS data of RSV and degradation product [M + H]+ ions and corresponding MS/MS data. The asterisk is used to denote diagnostic ions present only in specific isobaric MS/MS spectra.
Table 1. nanoLC-nanoESI-QTOF/MS data of RSV and degradation product [M + H]+ ions and corresponding MS/MS data. The asterisk is used to denote diagnostic ions present only in specific isobaric MS/MS spectra.
ProductsMolecular FormulaeExperimental Mass (Da)Theoretical Mass (Da)Mass Error (ppm)RDBMajor Fragments (Chemical Formula)
RSVC22H29N3O6FS+482.1760482.1761−0.219.5464.1653 (C22H27N3O5FS+), 446.1553 (C22H25N3O4FS+), 422.1549 (C20H25N3O4FS+), 404.1984 (C21H27N3O4F+), 378.1282 (C18H21N3O3FS+), 376.1484 (C19H23N3O2FS+), 314.1665 (C18H21N3OF+) 300.1508 (C17H19N3OF+), 282.1403 (C17H17N3F+), 272.1559 (C16H19N3F+), 270.1409 (C16H17N3F+), 258.1402 (C15H17N3F+), 256.1242 (C15H15N3F+), 230.1093 (C13H13N3F+), 189.0827 (C11H10N2F+), 133.0454 (C5H9O4+)
AC22H30N3O7S+480.1806480.18050.219.5462.1712 (C22H28N3O6S+), 444.1599 (C22H26N3O5S+), 420.1600 (C20H26N3O5S+), 402.2024 (C21H28N3O5+), 376.1327 (C18H22N3O4S+), 312.1708 (C18H22N3O2+), 298.1554 (C17H20N3O2+), 280.1446 (C17H18N3O+), 270.1600 (C16H20N3O+), 268.1446 (C16H18N3O+), 256.1446 (C15H18N3O+), 254.1293 (C15H16N3O+), 199.0873 (C12H11N2O+), 187.0870 (C11H11N2O+), 131.0496 (C9H7O+)
B.1/B.2C22H31N3O7FS+500.1865500.1867−0.408.5482.1767 (C22H29N3O6FS+), 464.1646 (C22H27N3O5FS+), 446.1538 (C22H25N3O4FS+), 422.1540 (C20H25N3O4FS+), 404.1974 (C21H27N3O4F+), 378.1268 (C18H21N3O3FS+), 376.1470 (C19H23N3O2FS+), 350.1330 (C17H21N3O2FS+), 300.1502 (C17H19N3OF+), 288.1495 (C16H19N3OF+), 281.0492 (C11H11N3O4S+), 270.1400 (C16H17N3F+), 258.1398 (C15H17N3F+), 256.1243 (C15H15N3F+), 228.0807 (C9H14N3O2S+), 201.0836 (C12H10N2F+), 189.0823 (C11H10N2F+), 175.0736 * (C9H9N3O+), 147.0663 * (C6H11O4+), 133.0459 (C5H9O4+)
C.1/C.2C22H29N3O7FS+498.1709498.1710−0.209.5480.1595 (C22H27N3O6FS+), 462.1502 (C22H25N3O5FS+), 438.1485 (C20H25N3O5FS+), 420.1923 (C21H27N3O5F+), 394.1230 (C18H21N3O4FS+), 342.1599 (C19H21N3O2F+), 317.1476 (C17H20N3O2F+), 316.1459 (C17H19N3O2F+), 298.1350 (C17H17N3OF+), 296.1195 (C17H15N3OF+), 288.1506 (C16H19N3OF+), 287.1384 (C16H18N3OF+), 286.1352 (C16H17N3OF+), 274.1350 (C15H17N3OF+), 273.1260 (C15H16N3OF+), 272.1192 (C15H15N3OF+), 258.1397 (C15H17N3F+), 246.1033 (C13H13N3OF+), 217.0767 (C12H10N2OF+), 189.0838 (C10H11N3O+)
D.1/D.2C22H29N3O8FS+514.1655514.1659−0.789.5496.1547 (C22H27N3O7FS+), 478.1418 (C22H25N3O6FS+), 452.1666 (C21H27N3O5FS+), 436.1880 (C21H27N3O6F+), 436.1346 (C20H23N3O5FS+), 418.1776 (C21H25N3O5F+), 408.1402 (C19H23N3O4FS+), 402.1820 (C21H25N3O4F+), 400.1643 (C21H23N3O4F+), 366.0923 (C16H17N3O4FS+), 352.1123 (C16H19N3O3FS+), 328.1451 (C18H19N3O2F+), 314.1311 (C17H17N3O2F+), 302.1279 (C16H17N3O2F+), 289.1178 (C15H16N3O2F+), 288.1143 (C15H15N3O2F+), 281.0518 (C11H11N3O4S+), 274.1363 (C15H17N3OF+), 265.0165 (C10H7N3O4S+), 218.1002 (C12H14N2O2+), 147.0668 (C6H11O4+)
EC22H27N3O6FS+480.1600480.1605−1.0410.5462.1492 (C22H25N3O5FS+), 436.1700 (C21H27N3O4FS+), 420.1756 (C21H27N3O3FS+), 392.1440 (C19H23N3O3FS+), 378.1284 (C18H21N3O3FS+), 358.1205 (C18H17N3O4F+), 340.1087 (C18H15N3O3F+), 314.1665 (C18H21N3OF +), 300.1505 (C17H19N3OF+), 298.1350 (C17H17N3OF+), 282.1402 (C17H17N3F+), 270.1403 (C16H17N3F+), 270.1042 (C15H13N3OF+), 256.1244 (C15H15N3F+), 201.0826 (C12H10N2F+), 189.0830 (C11H10N2F+), 189.0830 (C12H13O2+), 177.1034 (C10H13N2O+), 149.0713 (C10H10F+)
FC21H27N3O4FS+436.1711436.17070.929.5378.1288 (C18H21N3O3FS+), 300.1506 (C17H19N3OF+), 270.1403 (C16H17N3F+), 257.1295 (C15H16N3F+)
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Dončević, L.; Svetličić, E.; Hozić, A.; Mihaljević, B.; Jarmużek, D.; Tartaro Bujak, I.; Pluskota-Karwatka, D.; Ozdanovac, L.; Džeba, I.; Cindrić, M. NanoUPLC-QTOF-MS/MS Determination of Major Rosuvastatin Degradation Products Generated by Gamma Radiation in Aqueous Solution. Pharmaceuticals 2021, 14, 1160. https://doi.org/10.3390/ph14111160

AMA Style

Dončević L, Svetličić E, Hozić A, Mihaljević B, Jarmużek D, Tartaro Bujak I, Pluskota-Karwatka D, Ozdanovac L, Džeba I, Cindrić M. NanoUPLC-QTOF-MS/MS Determination of Major Rosuvastatin Degradation Products Generated by Gamma Radiation in Aqueous Solution. Pharmaceuticals. 2021; 14(11):1160. https://doi.org/10.3390/ph14111160

Chicago/Turabian Style

Dončević, Lucija, Ema Svetličić, Amela Hozić, Branka Mihaljević, Dorota Jarmużek, Ivana Tartaro Bujak, Donata Pluskota-Karwatka, Luka Ozdanovac, Iva Džeba, and Mario Cindrić. 2021. "NanoUPLC-QTOF-MS/MS Determination of Major Rosuvastatin Degradation Products Generated by Gamma Radiation in Aqueous Solution" Pharmaceuticals 14, no. 11: 1160. https://doi.org/10.3390/ph14111160

APA Style

Dončević, L., Svetličić, E., Hozić, A., Mihaljević, B., Jarmużek, D., Tartaro Bujak, I., Pluskota-Karwatka, D., Ozdanovac, L., Džeba, I., & Cindrić, M. (2021). NanoUPLC-QTOF-MS/MS Determination of Major Rosuvastatin Degradation Products Generated by Gamma Radiation in Aqueous Solution. Pharmaceuticals, 14(11), 1160. https://doi.org/10.3390/ph14111160

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop